	Discovery Cohort - NCT02254811			Replication Cohort - NCT01398969		
	Capsule (n = 25)	Colonoscopy (n = 17)	*P* value	Fresh (n = 11)	Frozen (n = 13)	*P* value
Age, mean (SD), y	59.0 (19.7)	56.4 (18.7)	0.6624	74.3 (14.1)	71.6 (18.6)	0.7363
Females, No. (%)	21 (84.0%)	9 (52.9%)	0.0659	4 (36.4%)	9 (69.2%)	0.2305
Charlson comorbodity index, median	3 (2-5)	3 (0-4)	0.4353			
Immunosuppressed patients, No. (%)	2 (8.0%)	3 (17.6%)	0.6439	3 (27.3%)	1 (7.7%)	0.4637
Use of immune modulator, No. (%)						
Costicosteroid	0 (0%)	1 (5.9%)	0.8443			
Immunosuppresant	1 (4.0%)	1 (5.9%)	1	4 (36.4%)	3 (23.1%)	0.7926
Biologic	2 (8.0%)	1 (5.9%)	1	5 (45.5%)	4 (30.8%)	0.751
Body mass index (BMI), mean (SD)	25.3 (6.6)	27.0 (4.1)	0.3113			
Inpatient status at screening, No. (%)	3 (12%)	0 (0%)	0.3833	7 (63.6%)	6 (46.2%)	0.6561
PPI use prior to FMT, No. (%)	4 (16%)	1 (5.9%)	6111	5 45.5%)	5 (38.5%)	1
No. of RCDI episodes prior to FMT; median	3 (3-4)	3 (3-4)	0.3893	3 (2.5-4.0)	3 (3-4)	0.4641
Duration of RCDI prior to FMT, median	65 (49-96)	70 (57-135)	0.2648			
No. of CDI related hospital admissions, med	1 (0-2)	0 (0--0)	0.0057			
IBD, No. (%)						
Ulcerative colitis	2 (8.3%)	3 (1.8%)	0.6439			
Crohn's	2 (8.3%)	1 (5.9%)	1	2 (18.2%)	2 (15.4%)	1
Hemoglobin (g/dL), median	137 (129-144)	138 (132-144)	0.6079			
WBC (10^9/L), median	8 (6.8-8.6)	6.5 (5.1-6.9)	0.0143	15.30 (8.35-21.70)	8.9 (6.7-12.6)	0.2212
Albumin (g/L), median	40.5 (38.8-43.3)	40 (38-42)	0.5857	31 (28-34)	30 (24-34)	0.8557
CRP (mg/L), median	1.9 (0.9-5.8)	6.2 (1.3-10.2)	0.244			
Creatinine (mg/dL), median	70 (58.75-76)	70 (59-84)	0.7404	88 (69.5-127)	85 (64-128)	0.6849

Table 1. Participant baseline characteristics for the discovery and replication cohorts